KGX:XETRKION GROUP AG Analysis
Data as of 2026-06-19 - not real-time
€41.84
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
KION GROUP AG trades at €41.84, comfortably above its 20‑day SMA (≈€41.26) but still well under the 50‑day (≈€43.73) and 200‑day (≈€55.04) averages, signaling a short‑term technical bounce within a broader bearish backdrop. The MACD histogram is positive and the line sits above its signal, offering a *bullish* cue, while the RSI hovers around 50, suggesting no immediate over‑bought or over‑sold condition. Fundamentally, the stock appears **undervalued** – its trailing P/E of ~15 is less than half the industry average of 31, and the DCF‑derived fair value of €53.75 implies roughly 40 % upside. The price‑to‑book ratio of 0.88 places the market below book value, and a dividend yield of 1.5 % with a modest 29 % payout ratio points to a *sustainable* dividend. However, the balance sheet is leveraged (debt‑to‑equity ≈128 %) and 30‑day volatility exceeds 44 %, flagging notable risk.
The recent earnings call highlighted an improving order intake and a rise in adjusted EBIT margin to 7.4 %, supporting a *growth‑value blend* narrative. Analyst consensus remains optimistic (median target €59, “buy” rating) and the Fear‑Greed Index sits at “Extreme Greed,” indicating market enthusiasm. Investors should weigh the upside potential against high leverage, sector cyclicality, and elevated price swings when forming a position.
The recent earnings call highlighted an improving order intake and a rise in adjusted EBIT margin to 7.4 %, supporting a *growth‑value blend* narrative. Analyst consensus remains optimistic (median target €59, “buy” rating) and the Fear‑Greed Index sits at “Extreme Greed,” indicating market enthusiasm. Investors should weigh the upside potential against high leverage, sector cyclicality, and elevated price swings when forming a position.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support at €35.80
- Bullish MACD histogram suggests short‑term upside
- High 30‑day volatility raises downside risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value indicates ~40 % upside
- Improving EBIT margins and order intake
- Sustainable dividend with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Price below book value (P/B 0.88) offers a margin of safety
- Undervalued relative to peers (P/E ~15 vs industry ~31)
- Global footprint diversifies revenue streams despite leverage
Key Metrics & Analysis
Financial Health
Revenue Growth-0.60%
Profit Margin3.26%
P/E Ratio14.9
ROE6.14%
ROA2.28%
Debt/Equity127.55
P/B Ratio0.9
Op. Cash Flow€1.1B
Free Cash Flow€1.1B
Industry P/E31.4
Technical Analysis
TrendBearish
RSI50.0
Support€35.80
Resistance€46.26
MA 20€41.26
MA 50€43.73
MA 200€55.04
MACDBullish
VolumeIncreasing
Fear & Greed Index90.61
Valuation
Fair Value€53.75
Target Price€58.67
Upside/Downside40.23%
GradeUndervalued
TypeBlend
Dividend Yield1.50%
Risk Assessment
Beta0.02
Volatility44.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.